Bridion (sugammadex) adverse event reports that FDA received

Name: Reaction terms in FDA adverse event reports that name Bridion
Creator: Reported Reactions
License: https://creativecommons.org/publicdomain/zero/1.0/

Name type: Brand name
Generic name: Sugammadex

What a report is

A report is not proof that the drug was the cause of the event.

FDA says:

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview, section "Responsible use of the data". The site read the page on 2 Oct 2026. The data have the reports that FDA received through 30 Jun 2026.

FDA also says:

There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event. The information in these reports has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of these events.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.
Source: openFDA, Response of the drug event API (meta.disclaimer). The site read the page on 2 Oct 2026.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

Drug reports received through 30 Jun 2026. Device reports have a separate cutoff, 30 Sep 2026. Why a report count is not a rate.

Reports on file

From January 2010 to June 2026, FDA received 1,734 adverse event reports that name Bridion. In these reports the drug is a suspect or interacting product.

In the same period, 131 further reports name it only as a concomitant medicine. The counts on this page do not include these reports.

FDA received 51 reports in the 12 months to June 2026 and 114 in the 12 months before. FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

Of the 1,332,454 drug reports that FDA received in the 12 months to June 2026, 51 (under 0.1%) name Bridion. Reports from physicians were 37% of the reports that name Bridion and 21.9% of all drug reports.

The number of people who use the product is not in the data. A count is not a rate. A count of reports is not a count of events or of patients, because one event can have more than one report.

There are many instances of duplicative reports and some reports do not contain all the necessary information.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Suspect product

FDA records each drug in a report as suspect, concomitant or interacting. This page counts the reports in which Bridion is suspect or interacting. FDA says:

Any number of the drugs may be marked as suspect if thought to be responsible for one or more of the reactions, but that information is not validated.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Data version

openFDA FAERS release of 29 Oct 2026. Reports received through 30 Jun 2026.

Since the last update

FDA says:

Many factors can influence whether or not an event will be reported, such as the time a product has been marketed and publicity about an event.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

The information in these reports cannot be used to estimate the incidence (occurrence rates) of the events reported.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

The latest update of the FDA data, recorded on 28 Oct 2026, changed no count of this page.

In April to June 2026, FDA received 6 reports that name Bridion.
In January to March 2026, FDA received 5.
In April to June 2025, FDA received 26.

April to June 2026 is the latest closed quarter in the data. A closed quarter is a quarter for which the FDA files have most of the reports.

All updates Feed of updates (RSS)

Reaction lookup

These are the reaction terms that the reports record, with the number of reports for each term. Type a term or a plain word to find its count.

What this list leaves out

The table lists the 103 reaction terms that 5 or more reports record. A term with fewer than 5 reports is not in the table.

The site keeps reaction terms for 1,730 of the 1,734 reports (99.8%).

The reports of the other years are not in the counts.

So a count in the table can be lower than the count of FDA.

Find a reaction term

The table shows the first 50 of 103 terms.

Reaction terms in the reports that name Bridion, most reports first
Reaction term (MedDRA) and plain meaning	Reports	Share of the 1,734 reports
Bradycardiaslow heart rate	232	13.4%
Anaphylactic reactiona severe, sudden allergic reaction	223	12.9%
Cardiac arrestthe heart stopped	153	8.8%
Bronchospasmtightening of the airways	148	8.5%
Anaphylactic shocka severe allergic reaction with collapse	140	8.1%
Hypotensionlow blood pressure	109	6.3%
Recurrence of neuromuscular blockade	81	4.7%
Drug ineffectivethe medicine did not work as expected	73	4.2%
Oxygen saturation decreased	64	3.7%
Off label useused for a purpose or in a way not on the label	60	3.5%
Blood pressure decreaseda low blood pressure reading	59	3.4%
Dyspnoeashortness of breath	51	2.9%
Hypoxialow oxygen	41	2.4%
Maternal exposure during pregnancythe mother took the medicine during pregnancy	37	2.1%
Erythemaskin redness	34	2%
No adverse eventno adverse event was reported	34	2%
Respiratory arrestbreathing stopped	34	2%
Urticariahives	32	1.8%
Product use issuea problem in how the product was used	31	1.8%
Drug hypersensitivityan allergic-type reaction (the term names a medicine)	30	1.7%
Drug reaction with eosinophilia and systemic symptomsDRESS, a severe reaction with rash, fever and organ involvement	30	1.7%
Product use in unapproved indicationused for a purpose not on the label	30	1.7%
Rashskin rash	29	1.7%
Tachycardiafast heart rate	28	1.6%
Incorrect dose administeredthe wrong dose was given	26	1.5%
Kounis syndrome	26	1.5%
Angioedemadeep swelling of skin or mucous membranes	25	1.4%
Hypoventilation	25	1.4%
Pulmonary oedemafluid in the lungs	25	1.4%
Neuromuscular block prolonged	22	1.3%
Hypersensitivityan allergic-type reaction	21	1.2%
Astheniaweakness or lack of energy	20	1.2%
Respiratory failurethe lungs could not supply enough oxygen	20	1.2%
Endotracheal intubation	18	1%
Deaththe patient died; cause not stated by this term	17	1%
Laryngospasm	17	1%
Cardio-respiratory arrestthe heart and breathing stopped	16	0.9%
Drug effect incomplete	16	0.9%
Depressed level of consciousness	15	0.9%
Pruritusitching	15	0.9%
Underdoseless than the intended dose	15	0.9%
Cough	14	0.8%
Muscle twitching	14	0.8%
Pulseless electrical activity	14	0.8%
Ventricular fibrillationa chaotic rhythm from the lower heart chambers	14	0.8%
Adverse eventan unwanted medical event, type not specified	13	0.7%
Heart rate decreased	13	0.7%
Overdosea dose above the recommended amount	13	0.7%
Product prescribing issue	13	0.7%
Oedemaswelling from fluid	12	0.7%

Download all 103 terms of Bridion (CSV)

The counts add to more than 1,734 reports, because one report can record more than one term. FDA says:

No individual drug is connected to any individual reaction. When a report lists multiple drugs and multiple reactions, there is no way to conclude from the data therein that a given drug is responsible for a given reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

The CSV file has the same rows and the same limits. Its last row is a note that says so.

MedDRA term

The person who codes a report selects the preferred term that agrees best with the description of the reporter. The words under a term are the plain meaning that this site gives.

Not the label

The FDA-approved label of a product lists its adverse reactions. See the official pages at the end of this page.

Same ingredient, other names

Reporters write a brand name or a generic name. Each name has its own page and its own count.

Names of Sugammadex with a page, in the order generic names, brand names, names as reported
Name	Name type	Reports
Sugammadex	Generic name	441
Sugammadex sodium	Generic name	359
Bridion (this page)	Brand name	1,734

Sum of the separately reported names: 2,534. A report that names two of these names is in the sum two times. The sum is not the number of reports for the ingredient.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Outcomes by year

The table gives the outcomes that the reporters gave, in the terms of FDA.

Outcomes in the reports that name Bridion, by the year of the openFDA file that holds the report

The table continues to the right.

Year of the openFDA file	Reports	Serious	Death	Life-threatening	Hospitalization (initial or prolonged)	Disability or Permanent Damage	Other Serious (Important Medical Events)	Not serious
2010	2	2	0	0	0	1	1	0
2011	2	2	1	0	2	0	0	0
2013	53	53	1	29	14	1	41	0
2014	19	19	1	6	10	0	13	0
2015	14	12	0	5	6	1	10	2
2016	144	104	2	24	31	3	88	40
2017	206	152	3	42	53	5	130	54
2018	235	191	15	62	68	3	157	44
2019	195	162	9	47	61	4	144	33
2020	138	108	8	21	28	15	88	30
2021	146	98	6	36	25	3	84	48
2022	148	124	7	49	41	3	99	24
2023	187	162	3	91	43	2	124	25
2024	131	94	7	38	29	1	81	37
2025	99	75	4	24	23	1	50	24
2026	15	14	0	9	0	0	6	1

An outcome in a report is not proof that the drug was the cause. The reporter gives the outcome, and FDA does not verify it. FDA says:

The information in these reports has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of these events.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

The six headings with the names of FDA are the outcome terms of FDA. A report can have more than one outcome. The columns Serious and Not serious are the two values of the openFDA field serious. For the value serious, openFDA gives this description:

The adverse event resulted in death, a life threatening condition, hospitalization, disability, congenital anomaly, or other serious condition
Source: openFDA, Drug adverse event fields (YAML reference). The site read the page on 2 Oct 2026.

The year is the year of the openFDA file that holds the latest version of the report. It is not always the year in which FDA first received the report. The chart of the next section uses the year of first receipt. The latest year is not complete.

Reports by year and month

Reports that name Bridion, by the year in which FDA received them

The column of 2026 has an outline, because the year is not complete. It has the reports that FDA received through June 2026 only.

Show the figures of the chart as a table

Reports that name Bridion, by the year in which FDA received them
Year	Reports
2010	2
2011	2
2012	20
2013	40
2014	24
2015	27
2016	171
2017	197
2018	227
2019	195
2020	136
2021	153
2022	144
2023	179
2024	117
2025	89
2026	11

Reports that name Bridion, by month, five years to June 2026

FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

Why a count moves

A count moves for many reasons. The guide gives FDA's words about them.

Patients and reporters

Age of the patient in the reports that name Bridion
Age	Reports	Share
Under 2	40	2.3%
2 to 11	54	3.1%
12 to 17	43	2.5%
18 to 44	301	17.4%
45 to 64	368	21.2%
65 to 74	193	11.1%
75 and over	160	9.2%
Age not given	575	33.2%

Sex of the patient in the reports that name Bridion
Sex	Reports	Share
Female	798	46%
Male	705	40.7%
Unknown or not given	231	13.3%

Type of reporter in the reports that name Bridion
Reporter	Reports	Share
Physician	641	37%
Pharmacist	120	6.9%
Other health professional	340	19.6%
Lawyer	8	0.5%
Consumer or non-health professional	622	35.9%
Not given	3	0.2%

Age and sex are as the report gives them. The reporter is the primary source in the report. 50.8% of the reports give the United States as the country.

Reason for use

Reason for use (indication) that the reports of Bridion record
Indication as recorded (MedDRA)	Reports	Share
Neuromuscular blockade reversal	970	55.9%
Anaesthesia reversal	56	3.2%
Obstructive airways disorder	13	0.7%
Anaesthesia	12	0.7%
Surgery	11	0.6%
Neuromuscular blockade	8	0.5%

The reporter fills in the indication, and the field is often empty. Each share is of all 1,734 reports.

Drugs in the same reports

Other drugs that the reports of Bridion name, in any role, in order of name
Drug	Reports that name the two
Acetaminophen	68
Dexamethasone	67
Fentanyl	226
Fentanyl citrate	65
Lidocaine	62
Ondansetron	71
Propofol	349
Rocuronium	94
Rocuronium bromide	410
Sevoflurane	149

The table has the 10 drug names that these reports name most. Two names in one report says only that the report recorded the two. It says nothing about the part of a product in the event.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Pages near this one

Sugammadex same ingredient
Sugammadex sodium same ingredient
Bricanyl next in the A to Z list
Brigatinib next in the A to Z list
Breztri Aerosphere next in the A to Z list
Brilinta next in the A to Z list
Breztri next in the A to Z list
Brilique next in the A to Z list
Breyna next in the A to Z list
Brimonidine next in the A to Z list
Breyanzi next in the A to Z list
Brimonidine tartrate next in the A to Z list

These links are for navigation. No count selected them.

Official pages

DailyMed labels for BridionThe labels (prescribing information) that have this name, at the National Library of Medicine.
MedWatch Online Voluntary Reporting FormThe online form of FDA for a voluntary report.
MedWatch: The FDA Safety Information and Adverse Event Reporting ProgramThe page of the FDA program that receives reports about drugs and devices.
FDA Adverse Event Monitoring System (AEMS) Public DashboardThe public dashboard of FDA for adverse event reports on drugs and biologics.

The site checked these addresses on 2 Oct 2026. The links open in a new tab.

Cite this page

Reported Reactions. Bridion: adverse event reports that FDA received. https://reportedreactions.com/drug/bridion/ Source: U.S. Food and Drug Administration, openFDA Drug Adverse Event (FAERS) files, release of 29 Oct 2026. Reports received through 30 Jun 2026.

Where the data come from

The counts come from the openFDA Drug Adverse Event (FAERS) bulk files, release of 29 Oct 2026. The files have the reports that FDA received through 30 Jun 2026. A drug name is the name on the report. The site matches it to a brand name or a generic name of the National Drug Code Directory of 2 Nov 2026. A class is the pharmacologic class (EPC) of the FDA label.

A report is in the count when it names Bridion as a suspect or interacting product. The 131 reports that name it only as a concomitant medicine are not in the count. The site does not publish a report narrative, a lot number, a detail of a patient or the identity of a reporter. The record of FDA is the authority. See how the site counts reports, the data sources and the corrections page.

Questions

Do these reports show that Bridion was responsible for the reactions?

No. FDA says:

For any given report, there is no certainty that a suspected drug caused the event.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

A reaction can relate to the condition that the drug treats, to other medicines, or to something else.

Is this the list of reactions on the label of Bridion?

No. It is a count of what people reported to FDA: 1,734 reports from January 2010 to June 2026. The FDA-approved label of a product lists its adverse reactions. The official pages at the end of this page link to the labels.

Who sent these reports?

Physician (37%), consumer or non-health professional (35.9%) and other health professional (19.6%). These are the types of reporter for the reports that name this drug.

If a manufacturer receives an adverse event report, it is normally required to send the report to FDA.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

How does a person report an adverse event?

FDA runs MedWatch, a program that takes voluntary reports from health professionals, patients and consumers. The guide on how to report has the links.

To the top of the page